Le Lézard
Classified in: Business
Subject: STR

IIROC Trading Resumption - STUD


VANCOUVER, BC, May 16, 2023 /CNW/ - Trading resumes in:

Company: Stallion Discoveries Corp. 

TSX-Venture Symbol: STUD 

All Issues: Yes 

Resumption (ET): 1:15 pm 
At the open

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions


These press releases may also interest you

at 22:00
SAP SE today announced NEC Corporation (TSE: 6701 "NEC") has selected SAP S/4HANA Cloud through the RISE with SAP solution, running on Amazon Web Services (AWS). Together with implementation partner ABeam Consulting, the migration will leverage...

at 21:35
Foundry 415 Innovation Group has unveiled its new Startup BoostCamp workshop series designed to empower startups with the knowledge and strategies they need to overcome the most common challenges to scaling and achieving success in the US market....

at 21:05
Pomerantz LLP is investigating claims on behalf of investors of Primerica, Inc. ("Primerica" or the "Company") .  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.  ...

at 21:01
Pomerantz LLP is investigating claims on behalf of investors of Sage Therapeutics, Inc. ("Sage" or the "Company") .  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

at 21:00
ZIMLog, a global freight forwarding brand, proudly unveils its renewed structure, reflecting a blend of experience and innovation aimed at meeting the diverse and evolving needs of businesses worldwide. After more than 22 years of successful...

at 20:55
Pomerantz LLP is investigating claims on behalf of investors of Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980...



News published on and distributed by: